Tools
Teriparatide
Indications
Teriparatide is a recombinant fragment of human parathyroid hormone consisting of its first amino (N)-terminal 34 amino acids and a potent osteoanabolic agent. The drug has undergone multiple clinical trials that proved its safety and efficacy for the treatment of osteoporosis. In a seminal randomized placebo-controlled trial (n = 1637) by Neer et al (2001) in postmenopausal women with at least one prior vertebral fracture (the Fracture Prevention Trial), 20 mcg teriparatide administered daily (ie, the currently approved dose for prescription) decreased the risk for new vertebral fractures by 65% (RR = 0.35; 95% CI = 0.22-0.55) and nonvertebral fragility fractures by 53% (RR = 0.47; 95% CI = 0.25-0.88) and increased bone mineral density at lumbar spine by 9% and at the femoral neck by 3% over a median follow-up period of 21 months.[1]
Not only do other subsequent trials corroborate these effects in head-to-head comparison trials to available therapies such as alendronate and risedronate in postmenopausal women, but trials also replicate them in men and patients with a different etiology for osteoporosis such as glucocorticoid-induced osteoporosis, indicating activity independently of sex and through primary and secondary osteoporotic etiologies.[2][3][4][5][6]
Teriparatide has FDA approval for the following indications:
- Treatment of osteoporosis in postmenopausal women with a high risk for fracture[7]
- Increasing bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture[8]
- Treatment of men and women with systemic glucocorticoid-induced osteoporosis at high risk for fracture[9][10]
The American College of Obstetricians and Gynecologists (ACOG) guidelines for osteoporosis (2022) suggest teriparatide for postmenopausal osteoporosis with a high risk of fracture.[11] The American College of Rheumatology endorses the treatment with teriparatide for patients with glucocorticoid-induced osteoporosis having an increased risk of significant fracture.[12] "High risk for fracture’’ is defined in the FDA drug labeling as a history of osteoporotic fracture, multiple risk fracture factors, failure, or intolerance to other available osteoporosis therapy (eg, bisphosphonates).
2023 American College of Physicians guidelines for osteoporosis recommend that clinicians prescribe teriparatide followed by bisphosphonate to decrease the risk of fractures in females with primary osteoporosis having a very high risk of fracture.[13] However, while bisphosphonates help retain bone mineral density gains that tend to regress after terminating therapy with teriparatide, concomitant use should be avoided because bisphosphonates may blunt its anabolic effect.[14]
Given the availability of safe, effective, and less expensive therapies for osteoporosis, the exigence of high risk for fracture or intolerance or nonavailability of other medicines points to the fact that PTH analogs should be used as "last resort’’ treatment and reserved for severe osteoporosis (defined by WHO as BMD of T-score 2.5 or less plus at least one fragility fracture) because patients with severe osteoporosis have significant risk for fracture. In a meta-analysis of cohort studies of 15259 men and 44902 women with prior fractures, a personal history of previous fragility fracture increased the risk of any subsequent fracture by more than 86% compared to individuals without prior fracture (RR = 1.86; 95% CI = 1.75-1.98).[15] The high risk for fracture associated with severe osteoporosis makes these patients likely to derive the most clinical benefit from this therapy. Other than the approved indications for osteoporosis, the results of studies indicate possible benefits of teriparatide in fracture healing, hypoparathyroidism, osteonecrosis of the jaw, and periodontal disease.[16]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Effects on Bone Metabolism
In disease states associated with excess parathyroid hormone (PTH) in the blood, such as primary hyperparathyroidism, increased osteoclast activity, and accelerated bone resorption it may seem paradoxical that parathyroid hormone or its analogs can be a treatment for osteoporosis, a disease associated with accelerated bone loss. Ultimately, the difference in PTH effects on the bone stems from differences in the dose and pattern of exposure of bone to PTH. When under continuous exposure to PTH (eg, hyperparathyroidism), bone undergoes resorption more than formation, while intermittent exposure to low-dose PTH (like daily teriparatide administration) induces bone formation more than resorption. Although the underlying molecular mechanisms undergirding this variation in effect (ie, catabolic effect with sustained exposure vs anabolic effect with intermittent exposure) are largely unknown, some involved molecular signaling mechanisms have been elucidated.[17][18][19]
Teriparatide is an analog of PTH that binds through the N-terminal moiety to PTH type 1 receptors (PTH type 1R). PTH type 1R are G-protein coupled receptors (GPCR) expressed on surfaces of various cells, the most important of which in respect to the classical physiological actions of PTH on calcium and phosphate homeostasis and bone metabolism are osteoblasts, osteocytes, and renal tubular cells. Following ligand binding to the receptor, both Gs–mediated activation of adenylate cyclase and Gq-mediated activation of protein kinase C (PKC) occur.[19][20] Adenylate cyclase catalyzes the generation of the secondary messenger cAMP, which ultimately activates protein kinase A (PKA). Although PTH activates both PKA- and PKC-dependent signaling pathways, the PKA-dependent pathway is primarily used for its anabolic and catabolic effects on bone.[20]
The anabolic effects of (intermittent) PTH are mediated by (1) upregulated transcriptional expression of pro-osteoblastogenic growth factors like insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 (FGF2); (2) modulation of the Wnt/ß-catenin osteoanabolic signaling pathway by down-regulating the synthesis of the Wnt-antagonist sclerostin, and (3) increased expression and activity of Runx2 - a transcription factor essential for differentiation of osteoblasts.[17][19] These pathways lead to an increased osteoblast survival and number, which results in the new growth of trabecular and cortical bones. This mode of action stands in stark contrast to that of antiresorptive agents (ie, bisphosphonates, long-term estrogen, raloxifene, and nasal calcitonin). These agents inhibit osteoclast-mediated bone resorption and, by doing so, also inhibit new bone formation because the 2 processes of resorption and formation are tightly coupled.[14]
To exert its catabolic effects, PTH acts on the same receptors in osteoblasts and osteocytes, increasing the expression of pro-osteoclastogenic cytokines like receptor activator of nuclear factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor.[19][20] RANKL interacts with its receptor (RANK) on osteoclast hematopoietic precursor cells, promoting osteoclastic differentiation and activation. Two FDA-approved therapies for osteoporosis target these complex signaling mechanisms; denosumab is a RANKL inhibitor, and romosozumab is a sclerostin antagonist.[21]
Effects on Calcium and Phosphate Homeostasis
Teriparatide has the same actions as endogenous PTH on calcium and phosphate homeostasis (ie, it increases serum calcium and lowers serum phosphate). These effects are generated through the well-known effects of PTH on kidneys and bone. PTH stimulates distal tubular calcium reabsorption in the kidney, inhibits proximal tubular phosphate reabsorption, and activates the 1-alpha-hydroxylase enzyme in proximal tubules, which subsequently converts the filtered 25-hydroxyvitamin D to 1,25-dihydroxy vitamin D, the most active vitamin D metabolite. In bone, teriparatide mobilizes calcium from the bone matrix into circulation.
Pharmacokinetics
Absorption: Teriparatide is well absorbed after subcutaneous (SC) injection; the absolute bioavailability is approximately 95%. The peak serum concentrations are attained 30 minutes after SC injection.[22]
Distribution: The volume of distribution is approximately 0.12 L/kg.
Metabolism: Metabolism of teriparatide primarily occurs within the target cells. Teriparatide is metabolized into smaller peptides and amino acids in the liver.[23]
Excretion: Teriparatide is primarily excreted by the kidney. The elimination half-life of SC teriparatide is approximately 1 hour.
Administration
Available Dosage Forms, Strengths, and Adult Dosage
- Teriparatide administration is via SC injection into the abdominal wall or anterior thigh.
- The dosage is 20 mcg per day. Pens containing a 28-day supply of pre-filled 20 mcg doses are available.
- Administration should occur when the patient can sit or lie down in case orthostatic hypotension develops.
- The treatment duration restricting teriparatide therapy for 2 years has been revised. Treatment with teriparatide for more than 2 years can be considered in some patients with a high fracture risk. These patients may benefit from further treatment with teriparatide.[24]
- Patients should also be prescribed supplemental calcium and vitamin D during treatment.
Use in Specific Patient Population
Hepatic impairment: No clinical studies of teriparatide have been conducted in patients with hepatic impairment. Use with caution.
Renal impairment: Teriparatide increases serum uric acid levels at high doses in patients with renal impairment.[25] However, teriparatide has favorable outcomes on markers of osteoporosis in patients with renal impairment.[26]
Pregnancy considerations: In animal reproductive studies, pregnant mice were given SC teriparatide in supratherapeutic doses, resulting in congenital anomalies such as interrupted rib and extra vertebra. Use during pregnancy is not advised.
Breastfeeding considerations: In a case report requiring teriparatide treatment in a breastfeeding mother, no adverse outcomes were noted in the breastfeeding infant. The infant's serum calcium levels should be monitored.[27][28] However, whether teriparatide is present in breast milk remains unknown; no well-designed studies have been conducted. Consequently, clinicians should avoid prescribing teriparatide during breastfeeding.
Pediatric patients: Pediatric patients have a high risk of osteosarcoma due to open epiphysis. Use is contraindicated.[24]
Older patients: According to a study, no unexpected adverse effects were found in patients aged above 80 compared to other patients.[29]
Adverse Effects
Teriparatide is a well-tolerated drug. Short-term side effects reported by patients include nausea, headache, dizziness, and orthostatic hypotension.[30] Alterations of calcium metabolism are common, with hypercalcemia and hypercalciuria being the 2 most frequent side effects.[16] Hypercalcemia is most commonly mild and transient, and rarely (3% of patients taking 20 mcg/d) does it become persistent and require dose reduction or therapy discontinuation.[18] Although teriparatide increased renal calcium excretion from baseline, significant hypercalcemia or renal sequelae like nephrolithiasis and nephrosclerosis have not been reported.[14] Increased serum uric acid levels have been reported.[31][32] A 15-year post-marketing surveillance study demonstrated that teriparatide did not increase the risk of osteosarcoma. Risk factors identified were exposure to radiation and Paget disease of bone.[33]
Warnings
Osteosarcoma: The FDA has removed the box warnings regarding osteosarcoma. However, the FDA still recommends avoiding teriparatide in patients with predisposing conditions, which can increase the risk of osteosarcoma. Conditions include Paget disease of bone, history of primary or secondary skeletal malignancy, history of ionizing radiation involving the skeleton, pediatric and young patients with open epiphysis, and hereditary disorders increasing the risk of osteosarcoma. According to the American Association of Clinical Endocrinology (AACE) guidelines, teriparatide should be avoided in patients with increased alkaline phosphatase of skeletal origin.[24][34]
Calciphylaxis and cutaneous calcification: A potential risk of calciphylaxis and cutaneous calcification is apparent. Use caution in patients with risk factors for calciphylaxis, such as chronic kidney disease, autoimmune disorders, and concurrent warfarin or systemic corticosteroid use.[35]
Hypercalcemia: Teriparatide can cause hypercalcemia and may worsen hypercalcemia in patients with pre-existing hypercalcemia. Avoid the use of teriparatide in patients with primary hyperparathyroidism.[36]
Risk of Urolithiasis: Use in patients with hypercalciuria and urolithiasis should be considered after a risk-benefit evaluation, as teriparatide causes hypercalciuria, which promotes urinary stones. Monitor urinary calcium excretion.[37][38]
Drug-Drug Interaction
Risk of digoxin toxicity: Teriparatide-induced hypercalcemia may predispose patients to digitalis toxicity.[39] In a study of 15 healthy individuals, teriparatide with digoxin did not alter EKG findings.[40] However, caution is still advised as digoxin has a narrow therapeutic index.[30]
Contraindications
Teriparatide is contraindicated in patients with hypersensitivity to teriparatide or its excipients.[24]
Monitoring
Patients on teriparatide therapy should have serum calcium measurements monitored at 1 month of treatment, with subsequent follow-up intervals according to serum calcium level and at the prescriber's discretion. If hypercalcemia is present, the dose of supplemental calcium should be reduced first; if the readings do not return to baseline, treatment should be administered every other day; if hypercalcemia persists, treatment should be discontinued, and the patient should undergo a diagnostic evaluation to determine the cause of hypercalcemia.[14]
Bone mineral density requires evaluation 1-year post-first dose. Before starting treatment, serum and urinary calcium should be measured because hypercalcemia and hypercalciuria constitute contraindications to recombinant PTH therapy. American Association of Clinical Endocrinology guidelines suggest clinicians can consider monitoring bone turnover markers such as serum P1NP (procollagen type I N-terminal propeptide).[41]
Toxicity
The most concerning potential toxicity of teriparatide therapy is the risk of skeletal carcinogenicity, most notably osteosarcoma. Researchers detected the carcinogenic effect in Fisher rats subjected to the treatment of relatively high doses ranging from 5 to 75 mcg/kg/d for 2 years. The risk is considered to be minimal and nonsignificant in humans because of several lines of evidence: differences between rat and human skeletal physiologies, the fact that 2 years represent almost 90% of the rats' lifespan while representing only 2% to 3% of that of humans and the doses used are 3 to 58-fold the prescribed human dose, the detection of only 3 cases of osteosarcoma with unproven causality in over 1 million patients treated with teriparatide, and an ongoing post-marketing surveillance study of teriparatide use in humans showing no incident risk of osteosarcoma at 8-year interim analysis. The FDA previously limited approval to 2 years based on the Fisher rats toxicity study.[18][42][43]
According to product labeling, overdose symptoms are transient and identical to the most commonly reported side effects associated with therapeutic doses, such as nausea, vomiting, dizziness, and orthostatic hypotension. An older patient was administered supratherapeutic doses of teriparatide due to a dosing error, with no significant toxicity.[44] No antidote for teriparatide currently exists. In overdose, teriparatide should be discontinued, and supportive treatment should be provided with adequate hydration and careful monitoring of serum calcium and phosphorus levels.
Enhancing Healthcare Team Outcomes
Recombinant parathyroid hormone falls in a new category of osteoporosis therapy called anabolic therapy; teriparatide is the first approved drug in this category and has been shown to improve outcomes for patients with osteoporosis. As with any medication, teriparatide has potential side effects, most notably a theoretical risk of osteosarcoma. The interprofessional healthcare team should be aware of the rationale of using teriparatide and communicate the reasons for therapy effectively to their patients in a manner that assists the patient in making the best-informed decision and acknowledges both the possible adverse effects and the clinical benefit of this therapy (reduction in vertebral and nonvertebral fractures and strengthening of bones). Orthostatic hypotension is also a concern, and patients need to be informed about preventing and managing this potential adverse event. This issue is a high priority, especially in patients with osteoporosis, as a relatively minor fall for most people might result in a catastrophic fracture.[45] All interprofessional team members should counsel patients and monitor their response to treatment. Endocrinologists should be consulted for patients with a high risk of fractures. Interprofessional collaboration and open communication between physicians, advanced practice practitioners, specialists, nurses, and pharmacists can improve therapeutic outcomes related to teriparatide and mitigate potential adverse effects.
References
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England journal of medicine. 2001 May 10:344(19):1434-41 [PubMed PMID: 11346808]
Level 1 (high-level) evidenceKendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet (London, England). 2018 Jan 20:391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9 [PubMed PMID: 29129436]
Level 1 (high-level) evidenceKurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. The Journal of clinical endocrinology and metabolism. 2000 Sep:85(9):3069-76 [PubMed PMID: 10999788]
Level 1 (high-level) evidenceOrwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2003 Jan:18(1):9-17 [PubMed PMID: 12510800]
Level 3 (low-level) evidenceBody JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. The Journal of clinical endocrinology and metabolism. 2002 Oct:87(10):4528-35 [PubMed PMID: 12364430]
Level 1 (high-level) evidenceLiu CL, Lee HC, Chen CC, Cho DY. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clinical and investigative medicine. Medecine clinique et experimentale. 2017 Jun 26:40(3):E146-E157. doi: 10.25011/cim.v40i3.28394. Epub 2017 Jun 26 [PubMed PMID: 28653616]
Level 1 (high-level) evidenceWang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, Li K, Zhang YM. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. Medicine. 2017 May:96(21):e6970. doi: 10.1097/MD.0000000000006970. Epub [PubMed PMID: 28538396]
Level 2 (mid-level) evidenceBlick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs. 2008:68(18):2709-37. doi: 10.2165/0003495-200868180-00012. Epub [PubMed PMID: 19093708]
Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. The New England journal of medicine. 2007 Nov 15:357(20):2028-39 [PubMed PMID: 18003959]
Level 1 (high-level) evidenceSaag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis and rheumatism. 2009 Nov:60(11):3346-55. doi: 10.1002/art.24879. Epub [PubMed PMID: 19877063]
Level 1 (high-level) evidenceACOG Committee on Clinical Practice Guidelines–Gynecology. Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2. Obstetrics and gynecology. 2022 Apr 1:139(4):698-717. doi: 10.1097/AOG.0000000000004730. Epub [PubMed PMID: 35594133]
Level 1 (high-level) evidenceBuckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis care & research. 2017 Aug:69(8):1095-1110. doi: 10.1002/acr.23279. Epub 2017 Jun 6 [PubMed PMID: 28585410]
Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Clinical Guidelines Committee of the American College of Physicians, Cross JT Jr, Fitterman N, Lin JS, Maroto M, Obley AJ, Tice JA, Tufte JE. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Annals of internal medicine. 2023 Feb:176(2):224-238. doi: 10.7326/M22-1034. Epub 2023 Jan 3 [PubMed PMID: 36592456]
Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine reviews. 2005 Aug:26(5):688-703 [PubMed PMID: 15769903]
Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004 Aug:35(2):375-82 [PubMed PMID: 15268886]
Level 2 (mid-level) evidenceCheng ML, Gupta V. Teriparatide - Indications beyond osteoporosis. Indian journal of endocrinology and metabolism. 2012 May:16(3):343-8. doi: 10.4103/2230-8210.95661. Epub [PubMed PMID: 22629497]
Canalis E. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis. European journal of endocrinology. 2018 Feb:178(2):R33-R44. doi: 10.1530/EJE-17-0920. Epub 2017 Nov 7 [PubMed PMID: 29113980]
Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2012 Dec:27(12):2419-28. doi: 10.1002/jbmr.1800. Epub [PubMed PMID: 23165426]
Level 3 (low-level) evidenceJilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007 Jun:40(6):1434-46 [PubMed PMID: 17517365]
Level 3 (low-level) evidenceLee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Current opinion in nephrology and hypertension. 2009 Jul:18(4):298-302. doi: 10.1097/MNH.0b013e32832c2264. Epub [PubMed PMID: 19395963]
Level 3 (low-level) evidenceShakeri A, Adanty C. Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique. 2020 Jan 6:27(1):e25-e31. doi: 10.15586/jptcp.v27i1.655. Epub 2020 Jan 6 [PubMed PMID: 31922699]
Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcified tissue international. 2010 Dec:87(6):485-92. doi: 10.1007/s00223-010-9424-6. Epub 2010 Oct 16 [PubMed PMID: 20953593]
Level 1 (high-level) evidence. Teriparatide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31644031]
Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates. JBMR plus. 2022 Sep:6(9):e10665. doi: 10.1002/jbm4.10665. Epub 2022 Aug 14 [PubMed PMID: 36111201]
Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2007 Jan:18(1):59-68 [PubMed PMID: 17013567]
Level 1 (high-level) evidenceNishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clinical interventions in aging. 2016:11():1653-1659 [PubMed PMID: 27895472]
Level 2 (mid-level) evidence. Teriparatide. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 35442604]
Shulman D. Subcutaneous Infusion of rhPTH(1-34) During Pregnancy and Nursing in a Woman With Autosomal Dominant Hypoparathyroidism 1. Journal of the Endocrine Society. 2022 May 1:6(5):bvac031. doi: 10.1210/jendso/bvac031. Epub 2022 Feb 25 [PubMed PMID: 35350394]
Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. Journal of the American Geriatrics Society. 2006 May:54(5):782-9 [PubMed PMID: 16696744]
Level 1 (high-level) evidenceLucas C, Donovan P. 'Just a repeat' - When drug monitoring is indicated. Australian family physician. 2013 Jan-Feb:42(1-2):18-22 [PubMed PMID: 23529454]
Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011 Dec:26(12):2823-6. doi: 10.1002/jbmr.530. Epub [PubMed PMID: 21997141]
Level 3 (low-level) evidenceMinisola S, Cipriani C, Grotta GD, Colangelo L, Occhiuto M, Biondi P, Sonato C, Vigna E, Cilli M, Pepe J. Update on the safety and efficacy of teriparatide in the treatment of osteoporosis. Therapeutic advances in musculoskeletal disease. 2019:11():1759720X19877994. doi: 10.1177/1759720X19877994. Epub 2019 Oct 5 [PubMed PMID: 31632472]
Level 3 (low-level) evidenceGilsenan A, Midkiff K, Harris D, Kellier-Steele N, McSorley D, Andrews EB. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2021 Feb:36(2):244-251. doi: 10.1002/jbmr.4188. Epub 2020 Oct 13 [PubMed PMID: 32990990]
Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2020 May:26(Suppl 1):1-46. doi: 10.4158/GL-2020-0524SUPPL. Epub [PubMed PMID: 32427503]
Level 1 (high-level) evidenceKim J, Konkel K, Jones SC, Reyes M, McCulley L. Teriparatide-associated calciphylaxis: a case series. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2022 Feb:33(2):499-504. doi: 10.1007/s00198-021-06139-3. Epub 2021 Sep 8 [PubMed PMID: 34494145]
Level 2 (mid-level) evidenceMilosavljevic J, Thomas AM. Teriparatide Associated Late Hypercalcemia: A Report of Two Cases and Literature Review. Journal of community hospital internal medicine perspectives. 2022:12(1):54-58. doi: 10.55729/2000-9666.1010. Epub 2022 Jan 31 [PubMed PMID: 35711860]
Level 3 (low-level) evidenceLeder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (London, England). 2015 Sep 19:386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2 [PubMed PMID: 26144908]
Level 1 (high-level) evidenceLeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2022 Oct:33(10):2049-2102. doi: 10.1007/s00198-021-05900-y. Epub 2022 Apr 28 [PubMed PMID: 35478046]
Carswell AT, Eastman KG, Casey A, Hammond M, Shepstone L, Payerne E, Toms AP, MacKay JW, Swart AM, Greeves JP, Fraser WD. Teriparatide and stress fracture healing in young adults (RETURN - Research on Efficacy of Teriparatide Use in the Return of recruits to Normal duty): study protocol for a randomised controlled trial. Trials. 2021 Aug 30:22(1):580. doi: 10.1186/s13063-021-05556-3. Epub 2021 Aug 30 [PubMed PMID: 34461961]
Level 1 (high-level) evidenceBenson CT, Voelker JR. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. Clinical pharmacology and therapeutics. 2003 Jan:73(1):87-94 [PubMed PMID: 12545147]
Level 1 (high-level) evidenceEastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2019 May 1:104(5):1595-1622. doi: 10.1210/jc.2019-00221. Epub [PubMed PMID: 30907953]
Level 1 (high-level) evidenceVahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicologic pathology. 2002 May-Jun:30(3):312-21 [PubMed PMID: 12051548]
Level 3 (low-level) evidenceGilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo Patient Registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018 Oct:29(10):2335-2343. doi: 10.1007/s00198-018-4604-8. Epub 2018 Jul 5 [PubMed PMID: 29978254]
Cantrell L, Farson-Collier M. Clinical Course Following Supratherapeutic Teriparatide Dosing. The Annals of pharmacotherapy. 2011 Feb:45(2):281. doi: 10.1345/aph.1P705. Epub [PubMed PMID: 21304029]
Level 3 (low-level) evidenceMontero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J, Aguilar-Navarro S, Alexander NB, Becker C, Blain H, Bourke R, Cameron ID, Camicioli R, Clemson L, Close J, Delbaere K, Duan L, Duque G, Dyer SM, Freiberger E, Ganz DA, Gómez F, Hausdorff JM, Hogan DB, Hunter SMW, Jauregui JR, Kamkar N, Kenny RA, Lamb SE, Latham NK, Lipsitz LA, Liu-Ambrose T, Logan P, Lord SR, Mallet L, Marsh D, Milisen K, Moctezuma-Gallegos R, Morris ME, Nieuwboer A, Perracini MR, Pieruccini-Faria F, Pighills A, Said C, Sejdic E, Sherrington C, Skelton DA, Dsouza S, Speechley M, Stark S, Todd C, Troen BR, van der Cammen T, Verghese J, Vlaeyen E, Watt JA, Masud T, Task Force on Global Guidelines for Falls in Older Adults. World guidelines for falls prevention and management for older adults: a global initiative. Age and ageing. 2022 Sep 2:51(9):. doi: 10.1093/ageing/afac205. Epub [PubMed PMID: 36178003]